znf703 Antibody

What is ZNF703 and why is it significant in research?

ZNF703 (Zinc Finger Protein 703) is a 590 amino acid nuclear protein characterized by a single C2H2-type zinc finger domain crucial for transcriptional regulation . As a transcriptional corepressor that does not bind directly to DNA, ZNF703 regulates gene expression through recruitment of histone deacetylases to gene promoters . This protein plays critical roles in cell growth, differentiation, and development, with significant implications in cancer research and developmental biology .

The gene encoding ZNF703 is located on human chromosome 8, a region associated with numerous genetic disorders and malignancies, which highlights the importance of understanding ZNF703 function and interactions . Its involvement in multiple cellular processes makes it a valuable research target for understanding both normal development and pathological conditions.

What applications are ZNF703 antibodies most commonly used for?

ZNF703 antibodies demonstrate versatility across multiple laboratory techniques:

• Western Blotting (WB): For detecting and quantifying ZNF703 protein expression levels in cell or tissue lysates .

• Immunohistochemistry (IHC): For visualizing ZNF703 expression patterns in tissue sections, particularly in paraffin-embedded samples of tissues like breast carcinoma .

• Immunofluorescence (IF): For cellular localization studies showing that ZNF703 localizes to both the cytoplasm and nucleus .

• Immunoprecipitation (IP): For isolating ZNF703 protein complexes to study protein-protein interactions .

• ELISA: For quantitative detection of ZNF703 in solution .

• ChIP-seq and ChIP-PCR: For identifying genomic binding sites of ZNF703 and understanding its role in transcriptional regulation .

How do I select the appropriate ZNF703 antibody for my research?

Selecting the appropriate ZNF703 antibody requires consideration of several factors:

• Target species compatibility: Ensure the antibody detects ZNF703 in your species of interest. Available antibodies react with human, mouse, and rat ZNF703 proteins, with some offering cross-reactivity to dog, pig, cow, and other mammals .

• Application compatibility: Verify the antibody is validated for your specific application (WB, IHC, IF, ELISA, ChIP, etc.). For example, sc-271896 is validated for WB, IP, IF, IHC(P), and ELISA , while ABIN7248233 is specifically validated for ELISA and IHC .

• Epitope recognition: Consider which region of ZNF703 the antibody recognizes. Different antibodies target different epitopes:

  • Amino acids 150-250 (ab188031)

  • Amino acids 160-290 (CAB14325)

  • Amino acids 221-320, 226-254, 513-562, N-terminal, or C-terminal regions

• Antibody format: Choose between conjugated (HRP, PE, FITC, Alexa Fluor, biotin) or unconjugated formats based on your detection method .

• Clonality: Select between monoclonal (more specific) or polyclonal (potentially more sensitive) antibodies based on your experimental needs .

How can ZNF703 antibodies be used in ChIP-seq experiments to identify genomic binding sites?

ChIP-seq with ZNF703 antibodies requires careful optimization for identification of genomic binding sites. The procedure follows these methodological steps:

• Cell preparation: Culture approximately 5 × 10^7 cells (as demonstrated with OVCAR3 cells) in standard conditions with 10% FBS .

• Cross-linking and sonication: Cross-link cells to preserve protein-DNA interactions, then extract nuclear lysate and sonicate to fragment chromatin .

• Immunoprecipitation: Use highly specific ZNF703 monoclonal antibodies to precipitate the protein along with its bound DNA fragments .

• Library preparation and sequencing: Process the immunoprecipitated DNA for deep sequencing following standard ChIP-seq protocols .

• Data analysis pipeline:

  • Filter raw sequencing data to obtain high-quality reads

  • Align to the human genome (typically hg19 reference)

  • Perform de novo peak calling to identify binding regions

  • Conduct motif analysis of binding sites

  • Compare against control datasets to identify specific binding regions

This approach has been successfully employed to investigate ZNF703's role in transcriptional regulation in ovarian cancer, revealing its influence on downstream targets . The specificity of the antibody is crucial for minimizing background and identifying true binding sites.

What is the significance of ZNF703 subcellular localization and how can it be accurately determined?

ZNF703 exhibits dual localization to both the cytoplasm and nucleus, which has important implications for its function as a transcriptional regulator . This dynamic localization may reflect different functional states of the protein and potentially its involvement in signaling pathways.

Methodological approaches to accurately determine ZNF703 subcellular localization include:

• Immunofluorescence microscopy:

  • Fix cells in 4% paraformaldehyde (15 minutes at room temperature)

  • Permeabilize cell membranes

  • Incubate with ZNF703 antibody (1:500 dilution has been successful)

  • Counterstain nuclei with Hoechst 33342

  • Visualize using confocal microscopy

• Subcellular fractionation and Western blotting:

  • Separate nuclear and cytoplasmic fractions biochemically

  • Perform Western blot using ZNF703 antibody

  • Include proper loading controls for each fraction

• Co-localization studies:

  • Combine ZNF703 staining with markers of specific subcellular compartments

  • Analyze co-localization with nuclear transport proteins to assess regulation of nuclear import/export

The biological significance of ZNF703's subcellular distribution relates to its function as a transcriptional corepressor, where nuclear localization is essential for direct effects on gene expression, while cytoplasmic localization may indicate inactive states or non-transcriptional functions .

How can I optimize ZNF703 antibody use for detecting protein interactions through co-immunoprecipitation?

Optimizing co-immunoprecipitation (co-IP) experiments with ZNF703 antibodies requires careful consideration of several parameters:

• Antibody selection: Choose antibodies specifically validated for immunoprecipitation applications, such as sc-271896 (E-6) . Consider using agarose-conjugated versions (e.g., sc-271896 AC) to eliminate secondary antibody steps .

• Lysis buffer optimization:

  • Use non-denaturing buffers to preserve protein-protein interactions

  • Include appropriate detergents (e.g., 0.5% NP-40 or 1% Triton X-100)

  • Add protease and phosphatase inhibitors

  • Consider including EDTA to chelate metal ions that might disrupt zinc finger structures

• Cross-linking considerations:

  • For transient interactions, consider using reversible cross-linkers

  • Optimize cross-linking time and conditions to capture interactions without creating non-specific aggregates

• Controls:

  • Include IgG control from the same species as the ZNF703 antibody

  • Consider using ZNF703-depleted cells as negative controls

  • Include known interaction partners as positive controls when possible

• Detection strategies:

  • For western blot detection, use antibodies raised in different species than the IP antibody

  • Consider protein A/G conjugated to HRP for detection to avoid heavy chain interference

  • For mass spectrometry analysis, optimize elution conditions to maximize recovery

This approach has been successfully used to detect interactions between ZNF703 and other proteins, including HE4 in ovarian cancer research . The antibody's specificity and affinity are critical for successful co-IP experiments.

What are common issues with ZNF703 detection by Western blot and how can they be resolved?

When using ZNF703 antibodies for Western blot, researchers may encounter several challenges:

• Low signal strength:

  • Solution: Optimize antibody concentration (typically 1:500 to 1:2000 dilution range for most ZNF703 antibodies)

  • Solution: Increase protein loading (30μg of whole cell extract has been successful)

  • Solution: Enhance detection with amplification systems or more sensitive substrates

  • Solution: Consider using HRP-conjugated versions of the antibody for direct detection

• Multiple bands/non-specific binding:

  • Solution: Increase blocking time and concentration

  • Solution: Optimize washing steps (number, duration, buffer composition)

  • Solution: Use more specific monoclonal antibodies when available

  • Solution: Validate bands by including positive controls (e.g., cell lines known to express ZNF703) and negative controls

• Unexpected molecular weight detection:

  • Solution: ZNF703 has a calculated MW of 58kDa ; if bands appear at different sizes, consider post-translational modifications or alternative isoforms

  • Solution: Include known positive controls (e.g., MCF-7 cell line) to confirm correct band identification

  • Solution: Use recombinant ZNF703 as a positive control for size verification

• Poor reproducibility:

  • Solution: Standardize lysate preparation methods

  • Solution: Use fresh antibody aliquots and avoid freeze-thaw cycles

  • Solution: Carefully control transfer conditions, particularly for this nuclear protein

• Gel separation issues:

  • Solution: Optimize gel percentage (10% SDS-PAGE has been successful)

  • Solution: Adjust running conditions for proper separation of proteins in the 58kDa range

How should I optimize immunohistochemistry protocols for ZNF703 detection in different tissue types?

Optimizing immunohistochemistry (IHC) protocols for ZNF703 detection requires tissue-specific adjustments:

• Antigen retrieval optimization:

  • For most tissues, EDTA-based buffers (pH 8.0) like Trilogy™ with 15-minute heating provide effective retrieval

  • For challenging tissues, compare citrate buffer (pH 6.0) versus EDTA buffer (pH 8.0)

  • Optimize heating methods (microwave, pressure cooker, water bath) and duration

• Antibody dilution optimization:

  • Start with manufacturer recommendations (typically 1:50 to 1:200 for IHC-P)

  • For breast carcinoma tissue, 1:50 dilution has been validated

  • For colorectal carcinoma tissue, similar dilutions are effective

  • Perform titration experiments with serial dilutions to determine optimal concentration

• Incubation conditions:

  • Test both overnight incubation at 4°C versus 1-2 hours at room temperature

  • Optimize humidity control to prevent tissue drying

  • Consider using antibody diluents with background-reducing components

• Detection system selection:

  • For low expression tissues, use amplification systems (e.g., tyramide signal amplification)

  • For co-localization studies, consider fluorescence-based detection

  • For routine detection, HRP-polymer systems provide good sensitivity and lower background

• Controls and validation:

  • Include breast carcinoma tissue as a positive control

  • Include isotype controls to assess background

  • Consider using RNAi-treated tissues or ZNF703-negative tissues as negative controls

• Counterstaining optimization:

  • Adjust hematoxylin intensity to maintain visibility of nuclear ZNF703 staining

  • For dual staining, select compatible chromogens or fluorophores

These optimizations should be systematically documented to ensure reproducibility across different tissue types and experimental conditions.

What strategies can improve the specificity of ZNF703 detection in immunofluorescence experiments?

Improving specificity in immunofluorescence (IF) experiments for ZNF703 detection requires several methodological refinements:

• Fixation optimization:

  • 4% paraformaldehyde at room temperature for 15 minutes has been validated for MCF-7 cells

  • Compare with methanol fixation for potentially improved nuclear protein detection

  • Test shorter fixation times if epitope masking is suspected

• Permeabilization refinement:

  • Optimize detergent type (Triton X-100, Tween-20, saponin) and concentration

  • Adjust permeabilization time to balance antibody access versus preservation of cellular structures

  • For nuclear proteins like ZNF703, ensure adequate nuclear permeabilization

• Blocking enhancement:

  • Use species-matched serum (5-10%) combined with BSA (1-3%)

  • Consider commercial blocking solutions specifically designed for IF

  • Extend blocking time (1-2 hours) to reduce non-specific binding

• Antibody validation approaches:

  • Perform peptide competition assays to confirm specificity

  • Use cells with confirmed ZNF703 knockdown as negative controls

  • Compare staining patterns with multiple antibodies targeting different ZNF703 epitopes

• Signal-to-noise improvement:

  • Implement rigorous washing procedures between steps (3-5 washes)

  • Use 0.05-0.1% Tween-20 in wash buffers to reduce background

  • Consider using Sudan Black B (0.1-0.3%) to quench autofluorescence

• Co-localization strategies:

  • Combine ZNF703 staining with established nuclear markers

  • Use confocal microscopy with appropriate controls for bleed-through

  • Apply quantitative co-localization analysis to validate subcellular distribution

• Dilution optimization:

  • ZNF703 antibody dilution of 1:500 has been validated for IF in MCF-7 cells

  • Perform titration experiments to determine optimal concentration for your specific cell type

What is the role of ZNF703 in cancer development and how can antibodies help elucidate its mechanisms?

ZNF703's role in cancer development is multifaceted, with antibody-based research revealing several key mechanisms:

• Transcriptional regulation: As a transcriptional corepressor, ZNF703 regulates multiple genes involved in cell proliferation, adhesion, and migration . Antibody-based ChIP-seq studies have identified its genomic targets, providing insights into its regulatory network .

• Cancer-specific expression patterns: Immunohistochemical studies using ZNF703 antibodies have demonstrated upregulation in various cancers, including breast carcinoma and colorectal carcinoma . This differential expression suggests potential roles as a biomarker.

• Ovarian cancer progression: ZNF703 antibody research has revealed its role in promoting tumor progression in ovarian cancer . Studies using antibodies for detection have demonstrated interactions with other proteins, including HE4, suggesting complex regulatory mechanisms.

• Cellular migration and invasion: Antibody-based detection methods have shown ZNF703's contribution to cancer cell migration and invasion capabilities, potentially contributing to metastatic potential.

• Signaling pathway integration: Co-immunoprecipitation studies using ZNF703 antibodies have identified interactions with various signaling components, placing it within critical cancer-related pathways.

Research applications of ZNF703 antibodies in cancer research include:

• Prognostic evaluation through tissue microarray analysis

• Therapeutic target validation through detection of expression changes

• Mechanistic studies through ChIP-seq and protein interaction analyses

• Biomarker development through correlation with clinical outcomes

These applications highlight the importance of specific and sensitive ZNF703 antibodies in advancing our understanding of cancer biology and developing potential therapeutic strategies.

How does ZNF703 function in developmental processes and what antibody-based approaches can investigate this?

ZNF703 plays important roles in developmental processes, particularly in hindbrain development and cellular differentiation . Antibody-based approaches provide valuable tools for investigating these developmental functions:

• Developmental expression mapping:

  • Immunohistochemistry with ZNF703 antibodies can track expression patterns throughout embryonic development

  • Whole-mount immunostaining in model organisms can reveal spatial and temporal expression dynamics

  • Tissue-specific expression analysis can identify developmental programs potentially regulated by ZNF703

• Lineage-specific differentiation studies:

  • Immunofluorescence combined with lineage markers can identify cell types expressing ZNF703 during development

  • Flow cytometry with ZNF703 antibodies can quantify expression levels during differentiation processes

  • Single-cell analysis techniques can reveal heterogeneity in ZNF703 expression within developing tissues

• Functional interaction studies:

  • Co-immunoprecipitation with ZNF703 antibodies can identify developmental stage-specific protein interactions

  • Proximity ligation assays can visualize interactions in situ during development

  • ChIP-seq across developmental timepoints can track changes in genomic binding sites

• Developmental phenotype analysis:

  • Correlation of ZNF703 expression (detected by antibodies) with developmental phenotypes

  • Conditional knockout/knockdown validation using antibody-based detection of protein loss

  • Rescue experiments monitored through antibody detection of exogenous ZNF703

• Mammary gland development:

  • ZNF703 has been specifically implicated in mammary gland epithelial cell differentiation

  • Antibody-based detection can track expression during various stages of mammary development

  • Co-localization with established mammary differentiation markers can provide functional insights

These antibody-based approaches can help elucidate ZNF703's role in normal development, which in turn may provide insights into its functions in pathological conditions like cancer.

What are the emerging applications of ZNF703 antibodies in therapeutic development and biomarker research?

ZNF703 antibodies are finding increasing applications in therapeutic development and biomarker research:

• Biomarker development:

  • Immunohistochemical analysis of cancer tissues is revealing ZNF703 as a potential prognostic biomarker

  • Antibody-based tissue microarray studies can correlate ZNF703 expression with clinical outcomes

  • Quantitative assays (ELISA, Luminex) using ZNF703 antibodies may enable liquid biopsy applications

  • Multiplexed antibody panels including ZNF703 could improve diagnostic accuracy

• Therapeutic target validation:

  • Antibody-based screening can identify compounds that modulate ZNF703 expression or activity

  • ZNF703 antibodies enable monitoring of target engagement in drug development

  • Proximity-based assays using ZNF703 antibodies can identify compounds disrupting key protein interactions

  • ChIP-seq with ZNF703 antibodies can assess effects of potential therapeutics on genomic binding

• Combination therapy research:

  • Antibody-based detection of ZNF703 in pathways affected by existing therapies can suggest synergistic combinations

  • Monitoring ZNF703 expression or activity in response to treatments can identify resistance mechanisms

  • Correlation of ZNF703 levels with treatment response may guide personalized medicine approaches

• Cellular response monitoring:

  • ZNF703 responds to estradiol stimulus , suggesting potential applications in hormone-responsive cancers

  • Antibody-based detection can track ZNF703 changes following various treatments or stimuli

  • Time-course experiments using ZNF703 antibodies can reveal dynamic regulatory mechanisms

• Therapeutic antibody development:

  • While current ZNF703 antibodies are research tools, knowledge gained could inform development of therapeutic antibodies targeting accessible epitopes

  • Antibody-drug conjugates could potentially deliver cytotoxic payloads to ZNF703-expressing cells

  • Bispecific antibodies could link ZNF703-expressing cells to immune effector cells

These emerging applications highlight the potential of ZNF703 antibodies to bridge basic research with clinical applications, particularly in cancer diagnostics and therapeutics.

What are the key differences between monoclonal and polyclonal ZNF703 antibodies in research applications?

Monoclonal and polyclonal ZNF703 antibodies offer distinct advantages and limitations for research applications:

Selection considerations:

• For quantitative comparisons across experiments or samples, monoclonal antibodies offer better consistency

• For initial detection in new experimental systems, polyclonal antibodies may provide higher likelihood of detection

• For co-immunoprecipitation, monoclonal antibodies may provide cleaner results

• For applications requiring detection of multiple isoforms, polyclonal antibodies may be preferable

Both types have been successfully used for ZNF703 detection across various applications, with selection depending on specific experimental requirements and priorities.

How can I validate the specificity of a ZNF703 antibody for my experimental system?

Validating ZNF703 antibody specificity requires a multi-faceted approach:

• Genetic validation approaches:

  • Perform siRNA/shRNA knockdown of ZNF703 and verify decreased signal

  • Use CRISPR/Cas9 to generate ZNF703 knockout cells as negative controls

  • Overexpress ZNF703 (transfected 293T cells have been used) and confirm increased signal

• Peptide competition assays:

  • Pre-incubate antibody with the immunizing peptide

  • Compare signal with and without peptide competition

  • Specific binding should be significantly reduced after peptide competition

• Multiple antibody comparison:

  • Test multiple antibodies targeting different ZNF703 epitopes

  • Compare staining/detection patterns for consistency

  • Use both monoclonal and polyclonal antibodies when possible

• Cross-species reactivity assessment:

  • Test antibody in species with high ZNF703 homology

  • Compare detected molecular weights with predicted values

  • Verify that species specificity matches manufacturer claims

• Positive control samples:

  • Include known ZNF703-expressing samples (e.g., MCF-7 cells , breast carcinoma tissue )

  • Compare signal intensity with expected expression levels

  • Verify correct subcellular localization (cytoplasm and nucleus)

• Recombinant protein controls:

  • Use purified recombinant ZNF703 as a positive control

  • Verify antibody detects recombinant protein at expected molecular weight

  • Consider using tagged recombinant protein with independent detection method

• Application-specific validation:

  • For Western blot: Verify correct molecular weight (58kDa)

  • For IHC/IF: Confirm expected subcellular localization

  • For ChIP: Include input controls and IgG controls

• Method-independent validation:

  • Compare protein detection with mRNA expression data

  • Verify correlation between protein and transcript levels

  • Use proteomics approaches for independent protein identification

Thorough validation ensures experimental results are truly reflective of ZNF703 biology rather than artifacts of non-specific antibody binding.

What are the recommended storage and handling conditions to maintain ZNF703 antibody performance?

Proper storage and handling of ZNF703 antibodies are crucial for maintaining their performance across experimental applications:

• Storage temperature:

  • Store antibodies at -20°C for long-term storage

  • Avoid repeated freeze-thaw cycles by preparing single-use aliquots

  • For conjugated antibodies (HRP, fluorescent dyes), protect from light during storage

• Working dilution preparation:

  • Prepare fresh working dilutions on the day of use

  • Use high-quality, filtered buffers for dilution

  • For immunohistochemistry, prepare antibody dilutions in appropriate diluents with stabilizers

• Preservatives and stabilizers:

  • Most commercial ZNF703 antibodies contain preservatives (e.g., sodium azide)

  • Note that sodium azide is incompatible with HRP-based detection systems

  • Consider adding protein stabilizers (BSA, gelatin) to working dilutions

• Contamination prevention:

  • Use sterile technique when handling antibodies

  • Filter buffers used for antibody dilution

  • Avoid introducing bacteria or fungi that can degrade antibodies

• Transport conditions:

  • Transport on ice or with cold packs

  • Minimize exposure to extreme temperatures

  • Avoid prolonged periods at room temperature

• Stability monitoring:

  • Include positive controls in each experiment to monitor antibody performance over time

  • Document lot numbers and performance characteristics

  • Consider implementing stability testing program for critical antibodies

• Application-specific considerations:

  • For Western blot applications: Dilute in blocking buffer containing 0.1% Tween-20

  • For IHC applications: Use specialized diluents that enhance specificity

  • For IF applications: Filter antibody solutions to remove aggregates

• Antibody type-specific handling:

  • For agarose-conjugated antibodies (e.g., sc-271896 AC) : Avoid centrifugation at high speeds

  • For HRP-conjugated antibodies (e.g., sc-271896 HRP) : Protect from light and oxidizing agents

  • For fluorophore-conjugated antibodies: Minimize exposure to light at all stages

Following these guidelines will help ensure consistent performance and extend the useful life of ZNF703 antibodies in research applications.

How might new antibody technologies enhance ZNF703 research in the future?

Emerging antibody technologies hold significant promise for advancing ZNF703 research:

• Single-domain antibodies (nanobodies):

  • Smaller size may improve nuclear penetration for detecting ZNF703

  • Enhanced access to epitopes in native conformations

  • Potential for live-cell imaging of ZNF703 dynamics

  • Improved signal-to-noise ratio in super-resolution microscopy applications

• Recombinant antibody engineering:

  • Generation of highly specific recombinant ZNF703 antibodies with reduced batch-to-batch variation

  • Creation of bispecific antibodies targeting ZNF703 and interaction partners simultaneously

  • Development of antibody fragments optimized for specific applications

  • Humanized antibodies for potential therapeutic applications

• Spatially-resolved antibody-based detection:

  • Integration with spatial transcriptomics to correlate ZNF703 protein expression with gene expression patterns

  • Multiplexed imaging with cyclic immunofluorescence for comprehensive pathway analysis

  • Mass cytometry (CyTOF) with ZNF703 antibodies for single-cell protein analysis

  • Imaging mass cytometry for tissue-level ZNF703 detection with subcellular resolution

• Proximity-based detection methods:

  • Proximity ligation assays to visualize ZNF703 interactions in situ

  • FRET/BRET-based reporters utilizing ZNF703 antibodies or fragments

  • BioID or APEX2 proximity labeling to identify novel ZNF703 interaction partners

  • Split-protein complementation assays to study dynamic ZNF703 interactions

• Intrabody applications:

  • Development of intracellularly expressed antibodies against ZNF703

  • Targeted degradation of ZNF703 using proteolysis-targeting chimeras (PROTACs)

  • Modulation of ZNF703 activity in specific cellular compartments

  • Real-time tracking of endogenous ZNF703 dynamics

• Antibody-based sensors:

  • Development of biosensors for ZNF703 conformational changes

  • Creation of reporters for ZNF703 post-translational modifications

  • Sensors for monitoring ZNF703 nuclear translocation in real-time

  • Detection of ZNF703 interaction with DNA or chromatin components

These technological advances could significantly enhance our understanding of ZNF703's function in normal development and disease pathogenesis, potentially leading to new diagnostic and therapeutic approaches.

What research gaps remain in understanding ZNF703 function that could be addressed with antibody-based approaches?

Several critical research gaps in ZNF703 biology could be addressed using antibody-based approaches:

• Post-translational modification landscape:

  • Development of modification-specific antibodies to detect phosphorylation, SUMOylation, or other modifications

  • ChIP-seq with modification-specific ZNF703 antibodies to understand how modifications affect genomic binding

  • Correlation of specific modifications with ZNF703 function in different cellular contexts

• Tissue-specific interaction networks:

  • Co-immunoprecipitation combined with mass spectrometry across different tissues and cancer types

  • Proximity ligation assays to verify interactions in situ

  • Comparison of ZNF703 interactomes in normal versus diseased tissues

• Regulatory mechanisms controlling ZNF703 expression and activity:

  • Antibody-based detection of ZNF703 levels following various stimuli

  • Analysis of nuclear-cytoplasmic shuttling using compartment-specific fractionation

  • Investigation of protein stability and turnover rates in different cellular contexts

• Role in therapy resistance mechanisms:

  • Monitoring ZNF703 expression changes during acquisition of therapy resistance

  • Correlation of ZNF703 levels with treatment response

  • Identification of downstream effectors mediating resistance phenotypes

• Developmental roles beyond hindbrain development:

  • Comprehensive immunohistochemical analysis across embryonic development

  • Investigation of ZNF703's role in tissue-specific stem cell populations

  • Analysis of ZNF703 expression during cellular reprogramming

• Functional differences between ZNF703 isoforms:

  • Development of isoform-specific antibodies

  • Characterization of isoform-specific interactomes

  • Analysis of differential subcellular localization of isoforms

• Dynamics of ZNF703 genomic binding:

  • Time-course ChIP-seq studies following various stimuli

  • Analysis of pioneer factor activity in chromatin remodeling

  • Investigation of cooperative binding with other transcription factors

• Potential extracellular functions:

  • Exploration of potential secreted forms using antibody-based detection

  • Investigation of ZNF703 as a biomarker in liquid biopsies

  • Analysis of potential non-cell-autonomous effects

Addressing these research gaps would significantly advance our understanding of ZNF703 biology and potentially reveal new therapeutic targets or diagnostic approaches in diseases associated with ZNF703 dysregulation.